Home Home Home Inbox Home Search

Event

MMI-0100, a Novel MAPKAP Kinase II (MK2) Inhibitor, Delivered Via Inhalation, Displays an Excellent Safety and Tolerability Profile in Three Phase 1 Clinical Trials [Board No. 202]

Location: Board no. 202
Session Type: RAPiD: Rapid Abstract Poster Discussion Session
Wednesday
May
23
1:30 PM
3:30 PM

Speaker(s)/Author(s)

Cynthia Lander

PhD
Moerae Matrix

Brian Leaker

MD
Heart Lungs Center

J. van de Wetering

PhD
PRA Health Sciences

EJ van Hoogdalem

PhD
PRA Health Sciences

Andrew Luber

Pharm.D.
Moerae Matrix

Caryn Peterson

BSc
Moerae Matrix

Alyssa Panitch

PhD
University of California, Davis

Grant Nicholson

PhD
Respiratory Clinical Trials

View Abstract

MMI-0100, a Novel MAPKAP Kinase II (MK2) Inhibitor, Delivered Via Inhalation, Displays an Excellent Safety and Tolerability Profile in Three Phase 1 Clinical Trials

Parent Sessions

  • D103 - TRANSPLANT AND ILD POTPOURRI...
    05-23-2018 1:30 PM - 3:30 PM
    • Home Home Home Inbox Home Search